Compare Cross-Linking

1 Product

reset all

At-a-Glance

Description

FDA

CE Mark

Active Ingredients

Application

Status

Strength

remove

IV-MED 80

iVeena Delivery Systems

Mechanism of Action: It is believed that lysyl oxidases, a family comprising LOX and four LOX-like enzymes (LOXL1-4), catalyze the formation of collagen crosslinks and elastin and are implicated in the age-related corneal stiffening synonymous with keratoconus.
Dosage: One drop twice per day.

IVMED-80 is the first eye-drop, non-surgical, non-laser treatment for medical crosslinking of the cornea. The FDA granted orphan drug designation for IVMED-80 for the treatment of keratoconus in November 2017.

Orphan Drug Designation

Not specified

Topical

Prescription

Not specified

This content is intended for health care professionals and providers only. The information contained on Beye.com, including text, graphics, images, and interactive activities, is for informational purposes only, and is not intended to be a substitute for professional medical advice. Beye LLC, via its Editors and Publisher, accepts no responsibility for any injury or damage to persons or property occasioned through the implementation of any ideas or use of any product described herein. Although great care is taken to ensure that all information is accurate, it is recommended that readers seek independent verification of advice on drugs and other product usage, surgical techniques and clinical processes prior to their use. References made in article may indicate usage of medical equipment or drugs at dosages, for periods of time, and in combination not included in the current prescribing information. Inclusion of advertising materials on the website thereof, does not constitute and representation or guarantee by Beye LLC of the quality of such products, or of the claims made.